VHCP Management as of Sept. 30, 2016
Portfolio Holdings for VHCP Management
VHCP Management holds 24 positions in its portfolio as reported in the September 2016 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Dbv Technologies (DBVTF) | 31.9 | $33M | 457k | 71.12 | |
| Heron Therapeutics (HRTX) | 18.6 | $19M | 1.1M | 17.23 | |
| Coherus Biosciences (CHRS) | 8.1 | $8.2M | 306k | 26.78 | |
| Flamel Technologies | 6.1 | $6.2M | 500k | 12.40 | |
| Adverum Biotechnologies | 4.5 | $4.5M | 1.1M | 4.11 | |
| BioCryst Pharmaceuticals (BCRX) | 4.4 | $4.4M | 1.0M | 4.41 | |
| Lipocine | 3.7 | $3.8M | 850k | 4.46 | |
| Colucid Pharmaceuticals | 2.6 | $2.6M | 68k | 38.14 | |
| Axovant Sciences | 2.5 | $2.6M | 184k | 14.00 | |
| Ocera Therapeutics | 2.2 | $2.3M | 857k | 2.64 | |
| Zafgen | 2.0 | $2.0M | 602k | 3.31 | |
| Ascendis Pharma A S (ASND) | 1.8 | $1.8M | 90k | 20.10 | |
| Alcobra | 1.6 | $1.6M | 659k | 2.47 | |
| Beigene (ONC) | 1.5 | $1.6M | 51k | 30.80 | |
| D Stemline Therapeutics | 1.4 | $1.5M | 135k | 10.83 | |
| Achillion Pharmaceuticals | 1.4 | $1.5M | 180k | 8.10 | |
| Edge Therapeutics | 1.4 | $1.4M | 135k | 10.41 | |
| Akari Therapeutics | 1.3 | $1.3M | 158k | 8.51 | |
| ARCA biopharma | 1.3 | $1.3M | 462k | 2.83 | |
| Cytomx Therapeutics (CTMX) | 1.0 | $1.0M | 64k | 15.69 | |
| Regenxbio Inc equity us cm (RGNX) | 0.3 | $337k | 24k | 13.99 | |
| Audentes Therapeutics | 0.3 | $267k | 15k | 17.80 | |
| Pronai Therapeutics | 0.1 | $102k | 56k | 1.82 | |
| Aeglea Biotherapeutics | 0.0 | $38k | 6.0k | 6.33 |
